Analysts See Long-Term Gains From Takeda-Millennium Merger
This article was originally published in PharmAsia News
Although Takeda Pharmaceutical's takeover bid for Millennium Pharmaceuticals, a U.S. biotech, caused concerns among investors, other analysts see the move as good for the Japanese firm in the long run. The $8.8 billion offer, open to shareholders into May, would position Takeda to outpace other drug makers in the cancer-drug end of the business. The purchase also is seen as protection against revenue losses expected within the next three years as Takeda patents expire on some of its best-selling drugs. Analysts even believe that despite the immediate drain a merger would have on Takeda coffers, investors would benefit from the merger in the long run. (Click here for more - a subscription may be required
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.